A Review of Prostate Cancer Imaging, Positron Emission Tomography, and Radiopharmaceutical-based Therapy

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2020 Apr 8

PMID 32254013

Citations 1

Authors

Amy Pawson

Zonia Ghumman

Phillip H Kuo

Hossein Jadvar

Twyla Bartel

Bobby Shayegan

Katherine Zukotynski

Affiliations

Soon will be listed here.

Citing Articles

Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease.

Bobrowski A, Metser U, Finelli A, Fleshner N, Berlin A, Perlis N Can Urol Assoc J. 2021; 15(10):E545-E552.

PMID: 34665714 PMC: 8525523. DOI: 10.5489/cuaj.6988.

References

Bach-Gansmo T, Nanni C, Nieh P, Zanoni L, Bogsrud T, Sletten H . Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. J Urol. 2016; 197(3 Pt 1):676-683. PMC: 5645081. DOI: 10.1016/j.juro.2016.09.117. View

Hodge K, McNeal J, Terris M, Stamey T . Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989; 142(1):71-4; discussion 74-5. DOI: 10.1016/s0022-5347(17)38664-0. View

Brauer A, Grubert L, Roll W, Schrader A, Schafers M, Bogemann M . Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44(10):1663-1670. DOI: 10.1007/s00259-017-3751-z. View

Hamper U, Sheth S, Walsh P, Holtz P, Epstein J . Capsular transgression of prostatic carcinoma: evaluation with transrectal US with pathologic correlation. Radiology. 1991; 178(3):791-5. DOI: 10.1148/radiology.178.3.1994420. View

Fendler W, Calais J, Eiber M, Flavell R, Mishoe A, Feng F . Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019; 5(6):856-863. PMC: 6567829. DOI: 10.1001/jamaoncol.2019.0096. View

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M . German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2016; 58(1):85-90. DOI: 10.2967/jnumed.116.183194. View

Kratochwil C, Giesel F, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A . PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57(8):1170-6. DOI: 10.2967/jnumed.115.171397. View

Hamper U, Sheth S, Walsh P, Holtz P, Epstein J . Carcinoma of the prostate: value of transrectal sonography in detecting extension into the neurovascular bundle. AJR Am J Roentgenol. 1990; 155(5):1015-9. DOI: 10.2214/ajr.155.5.2120928. View

Pollen J, Witztum K, Ashburn W . The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984; 142(4):773-6. DOI: 10.2214/ajr.142.4.773. View

10.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

11.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T . Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. J Nucl Med. 2015; 56(12):1862-8. DOI: 10.2967/jnumed.115.162610. View

12.

Kulkarni H, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y . PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. 2016; 57(Suppl 3):97S-104S. DOI: 10.2967/jnumed.115.170167. View

13.

Schoder H, Herrmann K, Gonen M, Hricak H, Eberhard S, Scardino P . 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005; 11(13):4761-9. DOI: 10.1158/1078-0432.CCR-05-0249. View

14.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

15.

Sathianathen N, Butaney M, Bongiorno C, Konety B, Bolton D, Lawrentschuk N . Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018; 22(1):39-48. DOI: 10.1038/s41391-018-0075-4. View

16.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View

17.

Baum R, Kulkarni H, Schuchardt C, Singh A, Wirtz M, Wiessalla S . 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57(7):1006-13. DOI: 10.2967/jnumed.115.168443. View

18.

Andriole G, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff D . The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2018; 201(2):322-331. PMC: 7007765. DOI: 10.1016/j.juro.2018.08.050. View

19.

von Eyben F, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K . Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017; 45(3):496-508. PMC: 5787223. DOI: 10.1007/s00259-017-3895-x. View

20.

Fendler W, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus F . Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2016; 8(2):3581-3590. PMC: 5356905. DOI: 10.18632/oncotarget.12240. View